The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

被引:89
作者
Baptiste, N
Friedlander, P
Chen, XB
Prives, C [1 ]
机构
[1] Columbia Univ, Dept Biol Sci, New York, NY 10027 USA
[2] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA
关键词
p53; apoptosis; anti-neoplastics; proline-rich domain;
D O I
10.1038/sj/onc/1205015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wildtype p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53([gln22ser23]), is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53([gln22ser23]). Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.
引用
收藏
页码:9 / 21
页数:13
相关论文
共 115 条
  • [41] INDUCTION OF APOPTOSIS IN HELA-CELLS BY TRANS-ACTIVATION-DEFICIENT P53
    HAUPT, Y
    ROWAN, S
    SHAULIAN, E
    VOUSDEN, KH
    OREN, M
    [J]. GENES & DEVELOPMENT, 1995, 9 (17) : 2170 - 2183
  • [42] 14-3-3σ is a p53-regulated inhibitor of G2/M progression
    Hermeking, H
    Lengauer, C
    Polyak, K
    He, TC
    Zhang, L
    Thiagalingam, S
    Kinzler, KW
    Vogelstein, B
    [J]. MOLECULAR CELL, 1997, 1 (01) : 3 - 11
  • [43] ACTIVATION OF P53 SEQUENCE-SPECIFIC DNA-BINDING BY SHORT SINGLE STRANDS OF DNA REQUIRES THE P53 C-TERMINUS
    JAYARAMAN, L
    PRIVES, C
    [J]. CELL, 1995, 81 (07) : 1021 - 1029
  • [44] Covalent and noncovalent modifiers of the p53 protein
    Jayaraman, L
    Prives, C
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) : 76 - 87
  • [45] A transactivation-deficient mouse model provides insights into Trp53 regulation and function
    Jimenez, GS
    Nister, M
    Stommel, JM
    Beeche, M
    Barcarse, EA
    Zhang, XQ
    O'Gorman, S
    Wahl, GM
    [J]. NATURE GENETICS, 2000, 26 (01) : 37 - 43
  • [46] A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA
    KASTAN, MB
    ZHAN, QM
    ELDEIRY, WS
    CARRIER, F
    JACKS, T
    WALSH, WV
    PLUNKETT, BS
    VOGELSTEIN, B
    FORNACE, AJ
    [J]. CELL, 1992, 71 (04) : 587 - 597
  • [47] p53: Puzzle and paradigm
    Ko, LJ
    Prives, C
    [J]. GENES & DEVELOPMENT, 1996, 10 (09) : 1054 - 1072
  • [48] Kobayashi T, 1995, ONCOGENE, V11, P2311
  • [49] A p53-independent damage-sensing mechanism that functions as a checkpoint at the G(1)/S transition in Chinese hamster ovary cells
    Lee, HY
    Larner, JM
    Hamlin, JL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) : 526 - 531
  • [50] P53 AND ITS 14 KDA C-TERMINAL DOMAIN RECOGNIZE PRIMARY DNA-DAMAGE IN THE FORM OF INSERTION DELETION MISMATCHES
    LEE, S
    ELENBAAS, B
    LEVINE, A
    GRIFFITH, J
    [J]. CELL, 1995, 81 (07) : 1013 - 1020